4D Molecular Therapeutics (NASDAQ:FDMT) Announces Earnings Results

4D Molecular Therapeutics (NASDAQ:FDMT) issued its quarterly earnings results on Thursday. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.03), FiscalAI reports. 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. The company had revenue of $4.14 million during the quarter, compared to analysts’ expectations of $4.13 million.

4D Molecular Therapeutics Price Performance

Shares of 4D Molecular Therapeutics stock traded up $0.04 during trading hours on Friday, hitting $12.15. The company’s stock had a trading volume of 239,737 shares, compared to its average volume of 866,918. The company has a market cap of $670.95 million, a PE ratio of -4.62 and a beta of 2.92. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03. The business has a 50 day moving average price of $13.19 and a two-hundred day moving average price of $11.05. 4D Molecular Therapeutics has a 12-month low of $6.96 and a 12-month high of $16.93.

Insider Activity

In related news, insider David Kirn sold 58,333 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $12.92, for a total transaction of $753,662.36. Following the sale, the insider owned 709,153 shares of the company’s stock, valued at approximately $9,162,256.76. This trade represents a 7.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 122,155 shares of company stock worth $1,635,925 in the last three months. Company insiders own 7.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Thursday, October 15th. B. Riley Financial restated a “buy” rating on shares of 4D Molecular Therapeutics in a research note on Monday, August 17th. HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, October 22nd. Cantor Fitzgerald raised shares of 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price target on the stock in a report on Monday, September 14th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $32.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $30.22.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc. is a biotechnology company developing genetic medicines for serious diseases. Its research focuses on adeno-associated virus (AAV) gene therapies, which use engineered viral vectors to deliver therapeutic genetic material to cells. The company’s proprietary Therapeutic Vector Evolution platform is designed to create AAV vectors with targeted properties, including the ability to reach specific tissues. Its investigational programs have included treatments for retinal diseases, cystic fibrosis and Fabry disease.